Revlimid lenalidomide: Additional Phase II data

Additional data from an open-label, U.S. Phase II trial in 60 previously untreated patients >=65 years old showed that Revlimid led to an overall response rate (ORR) of 62%, with 15% achieving a complete response. At a median follow-up of 23 months, median progression-free survival (PFS) was not reached and overall survival (OS) was 90%. The most common grade 3/4 adverse events were neutropenia, thrombocytopenia and anemia. Patients received 5 mg/day Revlimid for the first 56 days of treatment and were then titrated up to 25 mg/day in 5 mg increments for days 1-21 of each 28-day cycle as tolerated. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...